AbbVie Inc (ABBV)vsMaravai Lifesciences Holdings Inc (MRVI)
ABBV
AbbVie Inc
$257.60
-2.16%
HEALTHCARE · Cap: $447.53B
MRVI
Maravai Lifesciences Holdings Inc
$6.59
-3.94%
HEALTHCARE · Cap: $2.47B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 30584% more annual revenue ($62.82B vs $204.73M). ABBV leads profitability with a 5.8% profit margin vs -51.1%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
MRVI
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-78.8%
Fair Value
$147.26
Current Price
$257.60
$110.34 premium
Intrinsic value data unavailable for MRVI.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Generating 3.6B in free cash flow
Revenue surging 40.5% year-over-year
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
Operating margin of 1.1%
Elevated debt levels
Weak financial health signals
ROE of -49.4% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.42 suggests the stock is reasonably priced for its growth.
Bull Case : MRVI
The strongest argument for MRVI centers on Revenue Growth. Revenue growth of 40.5% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 124.8x leaves little room for execution misses.
Bear Case : MRVI
The primary concerns for MRVI are Operating Margin, Debt/Equity, Piotroski F-Score.
Key Dynamics to Monitor
ABBV profiles as a value stock while MRVI is a hypergrowth play — different risk/reward profiles.
MRVI carries more volatility with a beta of 0.65 — expect wider price swings.
MRVI is growing revenue faster at 40.5% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 31/100) and 12.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Maravai Lifesciences Holdings Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Maravai LifeSciences Holdings, Inc., a life sciences company, offers products to enable the development of drug therapies, diagnostics, novel vaccines, and to support human disease research in the United States and internationally. The company is headquartered in San Diego, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?